Drug details:
Molecular formula: C₂₀H₂₄N₁₀O₉PS^-

Standard name: (2R,5R)-2-(6-aminopurin-9-yl)-5-[[[(2R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolane-3,4-diol

Synonym:

O-(((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl) O-((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl) phosphorothioate

Curated SMILES: C1=NC(=C2C(=N1)N(C=N2)[C@H]3C(C([C@H](O3)CO)OP(=S)([O-])OC[C@@H]4C(C([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)N

Evidence for compound's anti-virulence activity:

Mycobacterium
Related VFcategory: Immune modulation
Target: CdnP
Drug effect: Inhibits bacterial phosphodiesterase (PDE) CdnP activity that responsible for cleaving bacterial c-di-AMP as well as host-derived cGAMP to blunt the host's response to infection.
Max phase: Preclinical (in vivo)
Publication:
Dey RJ, et al., 2017. Inhibition of innate immune cytosolic surveillance by an M. tuberculosis phosphodiesterase. Nat Chem Biol 13(2):210-217.